334 related articles for article (PubMed ID: 10431020)
21. BT563 significantly decreases sIL-2R plasma levels despite acute allograft rejection.
Mueller AR; Platz KP; Steinmüller T; Nüssler N; Neumann U; Gerlach H; Stoll C; Bechstein WO; Neuhaus P
Transplant Proc; 1996 Dec; 28(6):3103-5. PubMed ID: 8962203
[No Abstract] [Full Text] [Related]
22. Reduction of early rejection in adult liver transplantation with ATG induction therapy.
Schulak J; May E; Post A; Fasola C; Mulligan D; Sterling R
Transplant Proc; 1997; 29(1-2):555-6. PubMed ID: 9123126
[No Abstract] [Full Text] [Related]
23. Interleukin-2 receptor antibody vs ATG for induction immunosuppression after liver transplantation: initial results of a prospective randomized trial.
Lemmens HP; Langrehr JM; Bechstein WO; Blumhardt G; Keck H; Lüsebrink R; Knoop M; Lohmann R; Tullius S; Lobeck H
Transplant Proc; 1995 Feb; 27(1):1140-1. PubMed ID: 7878826
[No Abstract] [Full Text] [Related]
24. Use of thymoglobulin induction therapy in the prevention of acute graft rejection episodes following liver transplantation.
Tchervenkov J; Flemming C; Guttmann RD; des Gachons G
Transplant Proc; 1997 Nov; 29(7A):13S-15S. PubMed ID: 9366919
[No Abstract] [Full Text] [Related]
25. Incidence and patterns of rejection using different induction therapies in liver transplant recipients.
Elkashab M; Reizig M; Greig PD; Cameron R; Phillips MJ; Chung S; Cattral M; Levy G
Transplant Proc; 1994 Oct; 26(5):2669-71. PubMed ID: 7940835
[No Abstract] [Full Text] [Related]
26. Induction therapy including antithymocyte globulin induces marked alterations in T lymphocyte subpopulations after liver transplantation: results of a long-term study.
Oertel M; Sack U; Kohlhaw K; Lehmann I; Emmrich F; Berr F; Hauss J; Schwarz R
Transpl Int; 2002 Oct; 15(9-10):463-71. PubMed ID: 12389078
[TBL] [Abstract][Full Text] [Related]
27. OKT3 as prophylaxis immunosuppression in pediatric liver transplant recipients.
Sommerauer JF; Atkison P; Howard J; Grant D; Wall W
Transplant Proc; 1994 Feb; 26(1):154-6. PubMed ID: 8108917
[No Abstract] [Full Text] [Related]
28. Antibody induction therapy in pancreas transplantation.
Gruessner RW
Transplant Proc; 1998 Jun; 30(4):1556-9. PubMed ID: 9636632
[No Abstract] [Full Text] [Related]
29. ABO incompatible liver transplantation in children: a prospective approach.
Renard TH; Shimaoka S; Le Bherz D; Conlin C; Andrews WS
Transplant Proc; 1993 Apr; 25(2):1953-6. PubMed ID: 8470241
[No Abstract] [Full Text] [Related]
30. Successful pancreas-renal transplantation without anti-T-cell antibody induction.
Shapiro ME; Abrams JM; Brown RS; Steinman TI; Strom TB
Transplant Proc; 1995 Dec; 27(6):3087-8. PubMed ID: 8539857
[No Abstract] [Full Text] [Related]
31. Induction immunosuppression with antithymocyte globulin in renal transplantation using a variable dose according to the absolute number of CD3+ T cells.
Abouna GM; Kumar MS; al-Abdullah IH; Loose J; Sullivan DK; Phillips K; Yost S; Seirka D
Transplant Proc; 1995 Oct; 27(5):2676-8. PubMed ID: 7482872
[No Abstract] [Full Text] [Related]
32. IL-2 antagonists: the European perspective.
Platz KP; Braun F; Fändrich F; Kremer B; Mueller AR
Transplant Proc; 2005 May; 37(4):1783-4. PubMed ID: 15919465
[TBL] [Abstract][Full Text] [Related]
33. Review and preview of anti-T-cell antibodies.
Helderman JH
Transplant Proc; 1995 Oct; 27(5 Suppl 1):8-9. PubMed ID: 7482824
[No Abstract] [Full Text] [Related]
34. Influence of multiple factors (age, transplant number, recipient category, donor source) on outcome of pancreas transplantation at one institution.
Gruessner A; Gruessner R; Moudry-Munns K; Dunn D; Najarian JS; Sutherland DE
Transplant Proc; 1993 Feb; 25(1 Pt 2):1303-5. PubMed ID: 8442121
[No Abstract] [Full Text] [Related]
35. Interleukin-2 receptor antibody therapy.
Ascher NL
Liver Transpl Surg; 1997 Nov; 3(6):643-4. PubMed ID: 9404968
[No Abstract] [Full Text] [Related]
36. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.
Emre S; Gondolesi G; Polat K; Ben-Haim M; Artis T; Fishbein TM; Sheiner PA; Kim-Schluger L; Schwartz ME; Miller CM
Liver Transpl; 2001 Mar; 7(3):220-5. PubMed ID: 11244163
[TBL] [Abstract][Full Text] [Related]
37. Comparison of CyA, OKT3, and ATG immunoprophylaxis in human liver transplantation.
Steininger R; Mühlbacher F; Hamilton G; Längle F; Gnant M; Popow T; Sautner T; Götzinger P; Wamser P; Stockenhuber F
Transplant Proc; 1991 Aug; 23(4):2269-71. PubMed ID: 1908154
[No Abstract] [Full Text] [Related]
38. Ventricular assist devices and aggressive immunosuppression: looking beyond overall survival.
Gonzalez-Stawinski GV; Cook DJ; Chang AS; Banbury MK; Navia JL; Hoercher K; Lober C; Atik FA; Taylor DO; Yamani MH; Young JB; Starling RC; Smedira NG
J Heart Lung Transplant; 2006 Jun; 25(6):613-8. PubMed ID: 16730565
[TBL] [Abstract][Full Text] [Related]
39. Effect of the HLA-DRw6 antigen in liver transplantation.
Saito S; Stratta RJ; Grazi GL; Castaldo P; Langnas AN; Wood RP; Shaw BW
Transplant Proc; 1991 Feb; 23(1 Pt 2):1430-1. PubMed ID: 1824899
[No Abstract] [Full Text] [Related]
40. Induction therapy with either anti-CD25 monoclonal antibodies or rabbit antithymocyte globulins in liver transplantation for hepatitis C.
Kamar N; Borde JS; Sandres-Saune K; Suc B; Barange K; Cointault O; Lavayssière L; Durand D; Izopet J; Rostaing L
Clin Transplant; 2005 Feb; 19(1):83-9. PubMed ID: 15659139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
